Clinical Trial Update: A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study of TAK-901 in subjects with advanced hematologic malignancies; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Multiple Myeloma
• Myelodysplastic Syndrome
• Myelogenous Leukemia
• Non-hodgkin Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• TAK-901

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Status: COMPLETED